A Phase 2 interventional study of LKA651 and Lucentis in Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 5 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 38th largest by enrollment, is the only one that started in 2019, is one of 19 in phase 2, and was the 83rd registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
39 studies in Macular Edema by Novartis: none open now, none under way, none of them phase 3. Of 37 finished, 25 (68%) have results posted.
Among the 39 studies in Macular Edema by Novartis, this one is the 23rd largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2019, is one of 4 in phase 2, and was the 33rd registered.
Novartis’s Macular Edema studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Novartis’s 39 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
This study was a 3-arm, parallel group, randomized, patient- and investigator-masked trial planned in 90 patients with Diabetic macular edema (DME). The study consisted of a screening period of 60 days, main study (12 weeks), and an extension period (12 weeks). The study was stratified such that sentinel safety cohorts were first enrolled to test the safety of the combination of LKA651 and Lucentis before proceeding with further patient randomization. After determination of safety from Day 15 data from each sentinel cohort, patients were enrolled into 1 of 3 arms: LKA651 monotherapy, LKA651 plus Lucentis, and Lucentis monotherapy. Every patient was dosed 3 times in 4 week intervals in the treatment phase and was then followed up for an extension phase of an additional 12 weeks during which Lucentis was allowed to be administered as rescue at the discretion of the Investigator. No predefined rescue criteria were outlined as guidance.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's enrollment of 91 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LKA651 Intravitreal injection
Drug: LKA651
LKA651 + Lucentis Intravitreal injection
Drug: LKA651 · Drug: Lucentis
Lucentis Intravitreal injection
Drug: Lucentis
Number of Participants With Adverse Events
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient. The severity of the AEs (mild, moderate, severe) was based on the Common Terminology Criteria for Adverse Events (CTCAE). Number of participants in each category is reported in the table. A participant who falls multiple times in one category is counted only once.
Time frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
Number of Participants With Ocular Adverse Events by Preferred Term in Study Eye
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.
Time frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
Number of Participants With Non-ocular Adverse Events (>=2%)
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.
Time frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
Intraocular Pressure (IOP) in Study Eye
Intraocular pressure was measured per the study site's regular practice.
Time frame: Screening, and Day 85
Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Charts in Study Eye
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. BCVA in study eye was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Baseline BCVA value and treatment naïve and treatment experienced variable were used as covariates. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
Time frame: Days 2, 8, 15, 29, 43, 57, and 85
Inner Macular Thickness (Inferior)
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
Time frame: Week 12 (Day 85)
Inner Macular Thickness (Temporal)
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
Time frame: Week 12 (Day 85)
Outer Macular Thickness (Inferior)
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
Time frame: Week 12 (Day 85)
Outer Macular Thickness (Temporal)
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
Time frame: Week 12 (Day 85)
Number of Participants Without Changes in Foveal Avascular Zone as Measured by Fluorescein Angiography (FA) in Study Eye
Foveal avascular zone was assessed by fluorescein angiography (FA).
Time frame: Days 29, 57, 85, End of Study (Up to Day 140)
Mixed Model Repeated Measures Analysis of Ratio to Baseline in Central Subfield Retinal Thickness (CSFT) in the Study Eye
Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT). Central subfield retinal thickness was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Log-transformed baseline central subfield retinal thickness and treatment naïve and treatment experienced variable were used as covariates. Results were back-transformed to show results as a ratio to baseline.
Time frame: Days 8, 15, 29, 43, 57, 85
Number of Participants Who Needed Retreatment With Anti-VEGF in Study Eye After Week 12
Time frame: Week 12 (Day 85) up to Day 140
Time to Retreatment in Study Eye With Anti-VEGF After Week 12
Time to retreatment with anti VEGF (as determined by the investigator) after Week 12 during the additional 12 week extension phase (that was up to 16 weeks after the last dose) was examined with a Kaplan Meier plot.
Time frame: Week 12 (Day 85) up to Day 140
Summary Statistics of Pharmacokinetics - Serum Concentrations of LKA651
PK parameters were determined using non-compartmental methods using the most recent version of WinNonlin Phoenix (Version 8.2). Concentrations below the lower limit of quantification (LLOQ) were treated as 1/2 LLOQ in summary statistics.
Time frame: Day 1 (0, 0.5 and 4 hrs post dose), Day 2, Day 8, Day 15, Day 29 (0, 0.5 and 4 hrs post dose), Day 43, Day 57 (0, 0.5 and 4 hrs post dose), Day 85
Summary Statistics of Pharmacokinetics - AUC0-28d of LKA651 (Serum)
Area under the curve over the dosing interval 0 to 28 days.
Time frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
Summary Statistics of Pharmacokinetics - Serum Concentrations of Lucentis
Time frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
Summary Statistics of Pharmacokinetics - AUC0-28d of Lucentis (Serum)
Area under the curve over the dosing interval 0 to 28 days.
Time frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
| Milestone | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Started | 28 | 30 | 33 |
| Completed | 21 | 27 | 31 |
| Not completed | 7 | 3 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 |
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient. The severity of the AEs (mild, moderate, severe) was based on the Common Terminology Criteria for Adverse Events (CTCAE). Number of participants in each category is reported in the table. A participant who falls multiple times in one category is counted only once.
| Participants | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| AEs, Patients with AEs | 20 | 16 | 19 |
| AEs of mild intensity | 16 | 15 | 19 |
| AEs of moderate intensity | 8 | 6 | 3 |
| AEs of severe intensity | 4 | 2 | 1 |
| Study drug-related AEs | 2 | 1 | 2 |
| Serious AEs | 3 | 4 | 1 |
| AEs leading to discontinuation of study treatment | 1 | 0 | 0 |
| Study-drug related AEs leading to discontinuation of study treatment | 1 | 0 | 0 |
| Non-serious AEs | 20 | 16 | 19 |
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.
| Participants | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Patients with at least one ocular AE in study eye | 11 | 7 | 9 |
| Conjunctival haemorrhage | 1 | 4 | 2 |
| Diabetic retinal oedema | 2 | 1 | 2 |
| Diabetic retinopathy | 1 | 1 | 1 |
| Visual acuity reduced | 3 | 0 | 0 |
| Vitreous haemorrhage | 1 | 0 | 2 |
| Dry eye | 0 | 1 | 1 |
| Macular oedema | 2 | 0 | 0 |
| Ocular hypertension | 2 | 0 | 0 |
| Abnormal sensation in eye | 0 | 0 | 1 |
| Anterior chamber flare | 0 | 1 | 0 |
| Corneal erosion | 1 | 0 | 0 |
| Cystoid macular oedema | 1 | 0 | 0 |
| Dacryostenosis acquired | 1 | 0 | 0 |
| Eye pain | 1 | 0 | 0 |
| Eyelids pruritus | 0 | 0 | 1 |
| Lenticular opacities | 0 | 0 | 1 |
| Punctate keratitis | 0 | 1 | 0 |
| Retinal cyst | 1 | 0 | 0 |
| Retinal detachment | 1 | 0 | 0 |
| Retinal exudates | 1 | 0 | 0 |
| Retinal haemorrhage | 1 | 0 | 0 |
| Vitreoretinal traction syndrome | 0 | 0 | 1 |
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.
| Participants | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Number of Participants With Non-ocular Adverse Events (>=2%) | 16 | 15 | 14 |
Intraocular pressure was measured per the study site's regular practice.
| mmHg | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Screening | 15.1 ± 3.20 | 14.9 ± 3.44 | 15.5 ± 2.88 |
| Day 85 | 15.5 ± 3.56 | 15.6 ± 3.67 | 15.2 ± 3.79 |
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. BCVA in study eye was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Baseline BCVA value and treatment naïve and treatment experienced variable were used as covariates. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
| Scores on a scale | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Day 2 | 61.5 (58.6 to 64.4) | 64.4 (62.3 to 66.6) | 64.1 (61.8 to 66.5) |
| Day 8 | 65.2 (61.7 to 68.7) | 68.6 (66.1 to 71.2) | 66.2 (63.4 to 69.0) |
| Day 15 | 65.9 (62.4 to 69.4) | 68.6 (65.8 to 71.4) | 68.4 (65.4 to 71.3) |
| Day 29 | 65.5 (62.6 to 68.4) | 68.2 (65.3 to 71.0) | 68.5 (65.9 to 71.1) |
| Day 43 | 67.8 (64.4 to 71.1) | 70.4 (67.6 to 73.3) | 69.1 (66.2 to 71.9) |
| Day 57 | 67.6 (64.7 to 70.5) | 71.5 (68.6 to 74.4) | 70.0 (67.4 to 72.6) |
| Day 85 | 67.8 (64.8 to 70.9) | 72.5 (69.5 to 75.4) | 70.5 (67.8 to 73.2) |
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
| micrometer | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Inner Macular Thickness (Inferior) | 503.06 ± 137.235 | 400.82 ± 53.180 | 390.48 ± 48.097 |
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
| micrometer | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Inner Macular Thickness (Temporal) | 505.27 ± 141.410 | 414.64 ± 67.032 | 404.93 ± 56.099 |
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
| micrometer | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Outer Macular Thickness (Inferior) | 388.66 ± 88.128 | 349.39 ± 44.538 | 342.88 ± 50.612 |
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
| micrometer | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Outer Macular Thickness (Temporal) | 404.60 ± 103.616 | 371.83 ± 70.124 | 352.24 ± 56.793 |
Foveal avascular zone was assessed by fluorescein angiography (FA).
| Participants | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Day 29 - NO CHANGE | 3 | 16 | 11 |
| Day 57 - NO CHANGE | 3 | 16 | 7 |
| Day 85 - NO CHANGE | 21 | 25 | 29 |
| End of Study (Up to Day 140) - NO CHANGE | 17 | 22 | 30 |
| End of Study (Up to Day 140) - CANNOT GRADE | — | 1 | — |
Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT). Central subfield retinal thickness was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Log-transformed baseline central subfield retinal thickness and treatment naïve and treatment experienced variable were used as covariates. Results were back-transformed to show results as a ratio to baseline.
| ratio | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Day 8 | 0.99 (0.92 to 1.07) | 0.83 (0.78 to 0.88) | 0.83 (0.78 to 0.88) |
| Day 15 | 0.97 (0.90 to 1.05) | 0.83 (0.78 to 0.88) | 0.80 (0.76 to 0.86) |
| Day 29 | 1.00 (0.94 to 1.05) | 0.80 (0.76 to 0.85) | 0.82 (0.78 to 0.86) |
| Day 43 | 1.04 (0.97 to 1.13) | 0.76 (0.71 to 0.81) | 0.79 (0.74 to 0.84) |
| Day 57 | 0.95 (0.89 to 1.00) | 0.75 (0.70 to 0.80) | 0.80 (0.76 to 0.84) |
| Day 85 | 0.97 (0.91 to 1.05) | 0.75 (0.70 to 0.80) | 0.78 (0.73 to 0.83) |
| Participants | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Number of Participants Who Needed Retreatment With Anti-VEGF in Study Eye After Week 12 | 16 | 16 | 21 |
Time to retreatment with anti VEGF (as determined by the investigator) after Week 12 during the additional 12 week extension phase (that was up to 16 weeks after the last dose) was examined with a Kaplan Meier plot.
| Days after Day 85 (Week 12) | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Time to Retreatment in Study Eye With Anti-VEGF After Week 12 | 55.0 (17.0 to NA) | 34.0 (12.0 to NA) | 31.0 (9.0 to 109.0) |
PK parameters were determined using non-compartmental methods using the most recent version of WinNonlin Phoenix (Version 8.2). Concentrations below the lower limit of quantification (LLOQ) were treated as 1/2 LLOQ in summary statistics.
| ng/mL | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| Day 1 - 0 hrs | 0.00 ± 0.00 | 0.00 ± 0.00 | — |
| Day 1 - 0.5 hrs post dose | 0.00 | 0.00 ± 0.00 | — |
| Day 1 - 4 hrs post dose | 114 ± 211 | 4.43 ± 17.1 | — |
| Day 2 | 36.3 ± 29.2 | 8.13 ± 21.6 | — |
| Day 8 | 16.2 ± 27.5 | 2.08 ± 8.06 | — |
| Day 15 | 7.24 ± 16.2 | 0.00 ± 0.00 | — |
| Day 29 - 0 hrs | 0.00 ± 0.00 | 0.00 ± 0.00 | — |
| Day 29 - 0.5 hrs post dose | 0.00 | 0.00 ± 0.00 | — |
| Day 29 - 4 hrs post dose | — | 7.60 ± 18.6 | — |
| Day 43 | 0.00 | 0.00 ± 0.00 | — |
| Day 57 - 0 hrs | 0.00 ± 0.00 | 0.00 ± 0.00 | — |
| Day 57 - 0.5 hrs post dos | 0.00 | 0.00 ± 0.00 | — |
| Day 57 - 4 hrs post dose | — | 0.00 ± 0.00 | — |
| Day 85 | 0.00 ± 0.00 | 0.00 ± 0.00 | — |
Area under the curve over the dosing interval 0 to 28 days.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Area under the curve over the dosing interval 0 to 28 days.
No measurements were reported for this outcome.
On-treatment deaths are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days). Post-treatment deaths are reported for the timeframe of greater than 30 days after last treatment, until study completion, up to approximately 168 days. All deaths refer to the sum of on-treatment and post-treatment deaths.
| Participants | LKA651 | LKA651 + Lucentis | Lucentis |
|---|---|---|---|
| On-Treatment Deaths | 0 | 0 | 0 |
| Post-Treatment Deaths | 1 | 0 | 0 |
| All Deaths | 1 | 0 | 0 |
Collected over Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LKA651 | 1/28 (3.6%) | 3/28 (10.7%) | 20/28 (71.4%) |
| LKA651 + Lucentis | 0/30 (0%) | 4/30 (13.3%) | 16/30 (53.3%) |
| Lucentis | 0/33 (0%) | 1/33 (3%) | 19/33 (57.6%) |
| Total | 1/91 (1.1%) | 8/91 (8.8%) | 55/91 (60.4%) |
| Event | LKA651 | LKA651 + Lucentis | Lucentis | Total |
|---|---|---|---|---|
| Retinal detachmentEye disorders | 1/28 | 0/30 | 0/33 | 1/91 |
| COVID-19 pneumoniaInfections and infestations | 1/28 | 0/30 | 0/33 | 1/91 |
| Haemorrhagic strokeNervous system disorders | 1/28 | 0/30 | 0/33 | 1/91 |
| Angina unstableCardiac disorders | 0/28 | 1/30 | 0/33 | 1/91 |
| Cyclic vomiting syndromeGastrointestinal disorders | 0/28 | 1/30 | 0/33 | 1/91 |
| Varices oesophagealGastrointestinal disorders | 0/28 | 1/30 | 0/33 | 1/91 |
| DehydrationMetabolism and nutrition disorders | 0/28 | 1/30 | 0/33 | 1/91 |
| Bone cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/28 | 1/30 | 0/33 | 1/91 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/28 | 1/30 | 0/33 | 1/91 |
| Confusional statePsychiatric disorders | 0/28 | 1/30 | 0/33 | 1/91 |
| Event | LKA651 | LKA651 + Lucentis | Lucentis | Total |
|---|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 1/28 | 5/30 | 2/33 | 8/91 |
| Diabetic retinal oedemaEye disorders | 3/28 | 1/30 | 2/33 | 6/91 |
| Visual acuity reducedEye disorders | 3/28 | 0/30 | 0/33 | 3/91 |
| HypertensionVascular disorders | 3/28 | 1/30 | 3/33 | 7/91 |
| Macular oedemaEye disorders | 2/28 | 0/30 | 0/33 | 2/91 |
| Ocular hypertensionEye disorders | 2/28 | 0/30 | 0/33 | 2/91 |
| COVID-19Infections and infestations | 2/28 | 0/30 | 0/33 | 2/91 |
| Blood creatinine increasedInvestigations | 2/28 | 0/30 | 0/33 | 2/91 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/28 | 1/30 | 1/33 | 4/91 |
| AnaemiaBlood and lymphatic system disorders | 1/28 | 2/30 | 1/33 | 4/91 |
| Age, Continuous(Years) | LKA651 | LKA651 + Lucentis | Lucentis | Total |
|---|---|---|---|---|
| Mean | 61.6 ± 8.58 | 63.8 ± 8.18 | 61.2 ± 9.02 | 62.2 ± 8.60 |
| Sex: Female, Male(Participants) | LKA651 | LKA651 + Lucentis | Lucentis | Total |
|---|---|---|---|---|
| Female | 9 | 13 | 10 | 32 |
| Male | 19 | 17 | 23 | 59 |
| Race (NIH/OMB)(Participants) | LKA651 | LKA651 + Lucentis | Lucentis | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 3 | 0 | 0 | 3 |
| White | 23 | 27 | 32 | 82 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2019 to primary completion in Jun 2022, 36 months.
Results were first posted in Oct 2023, 1 year 3 months after primary completion. A results delay was requested in May 2023.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 36 months is above that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LKA651 · Ranibizumab